THE CLINICAL DEVELOPMENT OF BIO-SIMILAR PRODUCTS OF INSULIN AND ITS ANALOGUES: MODERN STAGE OF PROGRESSING


Cite item

Full Text

Abstract

The article presents a review of data concerning clinical development of bio-similar products of recombinant human insulin and its analogues according beginning of 2017. The review is implemented concerning regulative requirements. The analysis is implemented concerning registries of registered medications and registries of clinical studies at the territory of the Russian Federation, European Union and USA. The review of articles in the information database MEDLINE (PubMed) is implemented too. It is established that in whole in the world regulative approaches are developed related to implementation of clinical studies of bio-similar products of insulin. However, this direction represents a new field of knowledge. The requirements to clinical studies of this type pass a stage of formation and adaptation. In the beginning of 2017 at the mentioned territories only two bio-similar insulin glargin were registered. At the same time, certain clinical studies at the present moment wait for completion. This situation testifies that the considered problem is one of the most actual and perspective fields of medical science.

About the authors

Anastasiya V. Philippova

The I.P. Pavlov first St. Peterburgsky state medical university of Minzdrav of Russia

Email: a.v.filippova2012@gmail.com
post-graduate student of the chair of clinical pharmacology and evidence medicine the I.P. Pavlov first St. Peterburgsky state medical university of Minzdrav of Russia, 197022, St. Peterburg, Russian Federation 197022, St. Peterburg, Russian Federation

V. Chzhao

The I.P. Pavlov first St. Peterburgsky state medical university of Minzdrav of Russia

197022, St. Peterburg, Russian Federation

A. S Kolbin

The I.P. Pavlov first St. Peterburgsky state medical university of Minzdrav of Russia; The St. Peterburgsky state university

197022, St. Peterburg, Russian Federation; 199106, St. Petersburg, Russian Federation

References

  1. Всемирная организация здравоохранения. Российская Федерация: Статистические данные. Available at: http://www.who.int/countries/rus/ru/
  2. World Health Organization World Health Organization. ВОЗ. Global Diabetes Report. 2015. Available at: http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf
  3. Дедов И.И., Шестакова М.В., Галстян Г.Р., Григорян О.Р., Есаян Р.М., Калашников В.Ю. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 7-й выпуск. Сахарный диабет. 2015; 18(Прил. 1): 1-112
  4. Sheldon B., Russell-Jones D., Wright J. Insulin analogues: an example of applied medical science. Diabetes Obes. Metab. 2009; 11(1): 5-19.
  5. Company Ely Lilly and Humalog NDA 020563; 1997. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020563a_s003_071697.pdf
  6. Novo Nordisk Inc Novolog NDA 020986; 2000. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/020986 Orig1s061.pdf
  7. US S.A. Apidra NDA 021629. Approval Letter; 2004. Available at: www.accessdata.fda.gov
  8. US S.A. Glargin NDA 021081; 2000. Available at: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM327015.pdf
  9. Novo Nordisk Inc Detemir NDA 021878; 2005. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021878s000_LevemirTOC.cfm
  10. Novo Nordisk Inc Degludec NDA 203314; 2015. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/203313and203314Orig1s000TOC.cfm
  11. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. European Medicines Agency; 2006. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf
  12. Guideline on Immunogenicity assessment of therapeutic proteins and peptides. European Medicines Agency; 2007. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003946.pdf
  13. Heinemann L., Hompesch M. Biosimilar insulins: how similar is similar? J. Diabetes Sci. Technol. 2011; 5(3):741-54.
  14. Guideline on the investigation of bioequivalence. European Medicines Agency; 2010. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf
  15. Owens D.R., Landgraf W., Schmidt A., Bretzel R.G., Kuhlmann M.K. The emergence of biosimilar insulin preparations - A cause for concern? Diabetes Technol. Ther. 2012; 14(11): 989-96.
  16. Heinemann L., Khatami H., McKinnon R., Home P. An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins. Diabetes Technol. Ther. 2015; 17(7): 1-17.
  17. Linnebjerg H., Lam E., Zhang X., Seger M.E., Coutant D., Chua L. et al. Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus. Diabetes Obes. Metab. 2017; 19(1): 33-9.
  18. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues. European Medicines Agency; 2015. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/03/WC500184161.pdf
  19. Oxford University Press Print Publication; 2010.
  20. Withdrawal Assessment Report for Insulin Human Rapid Marvel. European Medicines Agency; 2008. Available at: www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500067086.pdf
  21. Jimenez A.G., Brake B. Biosimilars in the European Union - regulatory perspectives. European Medicines Agency. Available at: http://www.ich.org/fileadmin/Public_Web_Site/Training/ASEAN_Q5C_workshop_May_2011/SESSION_IVa_Biosimilars.pdf
  22. Linnebjerg H., Lam E.C., Zhang X., Seger M.E., Coutant D., Chua L., et al. Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus. Diabetes Obes. Metab. 2017; 19(1): 33-9.
  23. Hadjiyianni I., Dahl D., Lacaya L.B., Pollom R.K., Chang C.L., Ilag L.L. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus(R) insulin glargine in patients with type 1 or type 2 diabetes mellitus. Diabetes Obes. Metab. 2016; 18(2): 159-68.
  24. Pollom R.K. Research letter. Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine. Diabetes Obes. Metab. 2016; 18(4): 425-9.

Copyright (c) 2017 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies